The Development of Selective Inhibitors of NagZ: Increased Susceptibility of Gram-Negative Bacteria to β-Lactams
Name
Stubbs-2013-Development of selective.pdf
Size
543.39 KB
Format
Adobe PDF
Checksum (MD5)
e8ea0e04d5214962b6ed3dbcac5a0ed1
Author(s)
Stubbs, Keith A.
Bacik, John-Paul
Perley-Robertson, G. Evan
Whitworth, Garrett E.
Gloster, Tracey M.
Vocadlo, David J.
Mark, Brian L.
Date Issued
September 2013
Journal
ChemBioChem
Publisher
Wiley Blackwell
Citation
Stubbs, Keith A. et al. “The Development of Selective Inhibitors of NagZ: Increased Susceptibility of Gram-Negative Bacteria to Β-Lactams.” ChemBioChem 14.15 (2013): 1973–1981.
Version
Final published version
Abstract
The increasing incidence of inducible chromosomal AmpC β-lactamases within the clinic is a growing concern because these enzymes deactivate a broad range of even the most recently developed β-lactam antibiotics. As a result, new strategies are needed to block the action of this antibiotic resistance enzyme. Presented here is a strategy to combat the action of inducible AmpC by inhibiting the β-glucosaminidase NagZ, which is an enzyme involved in regulating the induction of AmpC expression. A divergent route facilitating the rapid synthesis of a series of N-acyl analogues of 2-acetamido-2-deoxynojirimycin is reported here. Among these compounds are potent NagZ inhibitors that are selective against functionally related human enzymes. These compounds reduce minimum inhibitory concentration values for β-lactams against a clinically relevant Gram-negative bacterium bearing inducible chromosomal AmpC β-lactamase, Pseudomonas aeruginosa. The structure of a NagZ–inhibitor complex provides insight into the molecular basis for inhibition by these compounds.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1002/cbic.201300395
